Gynecological Cancer Diagnostics Market by Cancer Type (Uterine, Cervical, Ovarian, Vaginal, and Others), Test Type (Imaging Test, Screening Test, Biopsy, and Others), End User (Hospitals, Diagnostic Laboratories, Cancer Research Center, and Others), and Region 2023-2028

Gynecological Cancer Diagnostics Market by Cancer Type (Uterine, Cervical, Ovarian, Vaginal, and Others), Test Type (Imaging Test, Screening Test, Biopsy, and Others), End User (Hospitals, Diagnostic Laboratories, Cancer Research Center, and Others), and Region 2023-2028

Report Format: PDF+Excel | Report ID: SR112023A6870
Buy Now

Market Overview:

The global gynecological cancer diagnostics market size reached US$ XX Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ XX Billion by 2028, exhibiting a growth rate (CAGR) of XX% during 2023-2028. The rising awareness regarding gynecological cancer among the population and the increasing healthcare expenditure represent some of the key factors driving the market.

Gynecological cancer diagnostics refers to the numerous medical tests and procedures used to detect cancer in the female reproductive system. This includes cancers of the uterus, ovaries, cervix, fallopian tubes, and vulva. Some of the common diagnostic techniques for gynecological cancers include imaging testing (MRI, CT scan, ultrasound, etc.), screening tests (pap smear, colposcopy, HPV test, etc.), biopsies, and other procedures. These tests are performed in hospitals, cancer research institutes, diagnostics laboratories, cancer and radiation therapy centers, and specialty clinics to identify the presence of cancer in its early stages, when it is most treatable, and to monitor its progression. Additionally, cancer diagnostics help healthcare practitioners to develop a personalized treatment plan, evaluate specific antigens in a sample tissue by using antibodies, and provide better clinical outcomes through early diagnosis and care.

The rising incidences of various types of gynecological cancer, such as cervical, ovarian, endometrial, and vulvar cancers, coupled with the growing need for diagnostic technologies for better therapeutic effects, are primarily driving the global gynecological cancer diagnostics market. In addition to this, the emerging popularity of non-invasive diagnostic tests, including liquid biopsy and PCR-based tests, which are less invasive than traditional biopsy methods and can provide quick results, is also creating a positive outlook for the market. Moreover, the growing trend of personalized therapeutics along with the escalating utilization of polymerase chain reaction (PCR) and next-generation sequencing (NGS) for cancer detection is further bolstering the global market. Apart from this, the rising public awareness regarding the benefits of early disease detection and the importance of regular screenings of female reproductive organs is also propelling the market for gynecological cancer diagnostics. Additionally, the emerging trend of decentralized and patient-centric healthcare, which is further leading to an increased demand for point-of-care testing where the results are available quickly and can be used for immediate treatment decisions, is acting as another growth-inducing factor. Several other factors, including significant enhancements in the healthcare sector and the introduction of advanced oncological imaging modalities to detect lesions with high accuracy and reduced risk of false negative results, are expected to drive the gynecological cancer diagnostics market across the globe during the forecast period.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global gynecological cancer diagnostics market, along with forecasts at the global, regional, and country level from 2023-2028. Our report has categorized the market based on cancer type, test type and end-user.

Cancer Type Insights:

  • Uterine
  • Cervical
  • Ovarian
  • Vaginal
  • Others
     

The report has provided a detailed breakup and analysis of the gynecological cancer diagnostics  market based on the cancer type. This includes uterine, cervical, ovarian, vaginal and others. According to the report, uterine cancer represented the largest segment.

Test Type Insights:

  • Imaging Test
    • Ultrasound
    • MRI
    • CT Scan
    • Others
  • Screening Test
    • Pap Smear Test
    • Colposcopy
    • HPV Test
    • Others
  • Biopsy
    • Hysteroscopy
    • Endometrial Biopsy
  • Others
     

A detailed breakup and analysis of the gynecological cancer diagnostics market based on the test type has also been provided in the report. This includes imaging test, screening test, biopsy, and others.

End User Insights:

  • Hospitals
  • Diagnostic Laboratories
  • Cancer Research Center
  • Others
     

A detailed breakup and analysis of the gynecological cancer diagnostics market based on the end user has also been provided in the report. This includes hospitals, diagnostic laboratories, cancer research center and others. According to the report, hospitals accounted for the largest market share.

Regional Insights:

  • North America
    • United States
    • Canada
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Others
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa
     

The report has also provided a comprehensive analysis of all the major regional markets that include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and Middle East and Africa. According to the report, North America was the largest market for gynecological cancer diagnostics. Some of the factors driving the North America gynecological cancer diagnostics market included rapid technological advancements and faster adoption to new technologies in the diagnostics.

Competitive Landscape:

The report has also provided a comprehensive analysis of the competitive landscape in the global gynecological cancer diagnostics market. Competitive analysis such as market structure, market share by key players, player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have also been provided. Some of the companies covered include AbbVie Inc., Abbott Laboratories, Becton, Dickinson and Company, Eli Lilly, and Company, F-Hoffmann La Roche Ltd, GlaxoSmithKline Plc, Merck & Co., Inc., Quest Diagnostics Incorporated, Siemens Healthcare GmbH and Takeda Pharmaceutical Co. Ltd etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Report Coverage:

Report Features Details
Base Year of the Analysis 2022
Historical Period 2017-2022
Forecast Period 2023-2028
Units US$ Billion
Cancer Types Covered Uterine, Cervical, Ovarian, Vaginal, Others
Test Types Covered
  • Imaging Test: Ultrasound, MRI, CT Scan, Others
  • Screening Test: Pap Smear Test, Colposcopy, HPV Test, Others
  • Biopsy: Hysteroscopy, Endometrial Biopsy
  • Others
End Users Covered Hospitals, Diagnostic Laboratories, Cancer Research Center, Others
Regions Covered  Asia Pacific, Europe, North America, Latin America, Middle East and Africa
Countries Covered United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico
Companies Covered AbbVie Inc., Abbott Laboratories, Becton, Dickinson and Company, Eli Lilly, and Company, F-Hoffmann La Roche Ltd, GlaxoSmithKline Plc, Merck & Co., Inc., Quest Diagnostics Incorporated, Siemens Healthcare GmbH and Takeda Pharmaceutical Co. Ltd etc.
Customization Scope 10% Free Customization
Report Price and Purchase Option Single User License: US$ 4499
Five User License: US$ 5999
Corporate License: US$ 7499
Post-Sale Analyst Support 10-12 Weeks
Delivery Format PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)

Key Questions Answered in This Report:

  • How has the global gynecological cancer diagnostics market performed so far and how will it perform in the coming years?
  • What are the drivers, restraints, and opportunities in the global gynecological cancer diagnostics market?
  • What is the impact of each driver, restraint, and opportunity on the global gynecological cancer diagnostics market?
  • What are the key regional markets?
  • Which countries represent the most attractive gynecological cancer diagnostics market?
  • What is the breakup of the market based on the cancer type?
  • Which is the most attractive cancer type of gynecological cancer diagnostics market?
  • What is the breakup of the market based on the test type?
  • Which is the most attractive test type of gynecological cancer diagnostics market?
  • What is the breakup of the market based on end user?
  • Which is the most attractive end user of gynecological cancer diagnostics market?
  • What is the competitive structure of the global gynecological cancer diagnostics market?
  • Who are the key players/companies in the global gynecological cancer diagnostics market?

Key Benefits for Stakeholders:

  • IMARC’s report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the gynecological cancer diagnostics market from 2017-2028.
  • The research study provides the latest information on the market drivers, challenges, and opportunities in the global gynecological cancer diagnostics market.
  • The study maps the leading as well as the fastest growing regional markets. It further enables stakeholders to identify the key country-level markets within each region.
  • Porter's five forces analysis assist stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders to analyze the level of competition within the gynecological cancer diagnostics industry and its attractiveness.
  • Competitive landscape allows stakeholders to understand their competitive environment and provides an insight into the current positions of key players in the market.

Need more help?

  • Speak to our experienced analysts for insights on the current market scenarios.
  • Include additional segments and countries to customize the report as per your requirement.
  • Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
  • For further assistance, please connect with our analysts.
Gynecological Cancer Diagnostics Market by Cancer Type (Uterine, Cervical, Ovarian, Vaginal, and Others), Test Type (Imaging Test, Screening Test, Biopsy, and Others), End User (Hospitals, Diagnostic Laboratories, Cancer Research Center, and Others), and Region 2023-2028
Select License Type



Benefits of Customization

Personalize this research

Triangulate with your data

Get data as per your format and definition

Gain a deeper dive into a specific application, geography, customer, or competitor

Any level of personalization

Get in Touch With Us
UNITED STATES

Phone: +1-631-791-1145

INDIA

Phone: +91-120-433-0800

UNITED KINGDOM

Phone: +44-753-713-2163

Email: sales@imarcgroup.com

Client Testimonials

Aktive Services

IMARC made the whole process easy. Everyone I spoke with via email was polite, easy to deal with, kept their promises regarding delivery timelines and were solutions focused. From my first contact, I was grateful for the professionalism shown by the whole IMARC team. I recommend IMARC to all that need timely, affordable information and advice. My experience with IMARC was excellent and I can not fault it.

Read More
Greenfish S.A.

The IMARC team was very reactive and flexible with regard to our requests. A very good overall experience. We are happy with the work that IMARC has provided, very complete and detailed. It has contributed to our business needs and provided the market visibility that we required

Read More
Colruyt Group

We were very happy with the collaboration between IMARC and Colruyt. Not only were your prices competitive, IMARC was also pretty fast in understanding the scope and our needs for this project. Even though it was not an easy task, performing a market research during the COVID-19 pandemic, you were able to get us the necessary information we needed. The IMARC team was very easy to work with and they showed us that it would go the extra mile if we needed anything extra

Read More
KRISHAK BHARTI CO-OP LTD

Last project executed by your team was as per our expectations. We also would like to associate for more assignments this year. Kudos to your team.

Read More
Zee Media Corp. Ltd.

We would be happy to reach out to IMARC again, if we need Market Research/Consulting/Consumer Research or any associated service. Overall experience was good, and the data points were quite helpful.

Read More
Arabian Plastic Manufacturing Company Ltd.

The figures of market study were very close to our assumed figures. The presentation of the study was neat and easy to analyse. The requested details of the study were fulfilled. My overall experience with the IMARC Team was satisfactory.

Read More
Sumitomo Corporation

The overall cost of the services were within our expectations. I was happy to have good communications in a timely manner. It was a great and quick way to have the information I needed.

Read More
Hameln Rds

My questions and concerns were answered in a satisfied way. The costs of the services were within our expectations. My overall experience with the IMARC Team was very good.

Read More
Quality Consultants BV

I agree the report was timely delivered, meeting the key objectives of the engagement. We had some discussion on the contents, adjustments were made fast and accurate. The response time was minimum in each case. Very good. You have a satisfied customer.

Read More
TATA Advanced Systems Limited

We would be happy to reach out to IMARC for more market reports in the future. The response from the account sales manager was very good. I appreciate the timely follow ups and post purchase support from the team. My overall experience with IMARC was good.

Read More
Stax

IMARC was a good solution for the data points that we really needed and couldn't find elsewhere. The team was easy to work, quick to respond, and flexible to our customization requests.

Read More